Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | CCR8 | P51685 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743815 | 0.87 | KDM4E (0.48) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL6743812 | 0.87 | KDM4E (0.48) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL15602609 | 0.86 | KDM4E (0.37) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL452905 | 0.83 | — | — | |
| SCHEMBL31456930 | 0.74 | — | — | |
| SCHEMBL2537106 | 0.74 | — | — | |
| SCHEMBL4464036 | 0.74 | — | — | |
| SCHEMBL711331 | 0.74 | — | — | |
| SCHEMBL8948968 | 0.74 | — | — | |
| SCHEMBL13665338 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002536440-A | — | — | 2002-10-29 | — | — | JP | claimed |
| EP-1155007-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. Searle LLC (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2000047568-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. SEARLE LLC (US) | 2000-08-17 | — | — | WO | claimed |
| EP-1465885-A4 | NOVEL ALKYL/ARYL HYDROXY OR KETO THIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | PHARMACIA CORP (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6852753-B2 | Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | PHARMACIA CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1448546-A4 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | SEARLE LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1465885-A2 | NOVEL ALKYL/ARYL HYDROXY OR KETO THIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | Pharmacia Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | G.D. SEARLE, LLC | 2004-09-09 | — | — | US | disclosed |
| EP-1448546-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. Searle LLC (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6740663-B2 | ANTIHYPERLIPIDEMIC AGENTS | G.D. SEARLE, LLC | 2004-05-25 | — | — | US | disclosed |
| US-20040067872-A1 | Novel mono- and di-fluorinated benzothiepine compouds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | G.D. SEARLE, LLC (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030195218-A1 | Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003061604-A2 | NOVEL ALKYL/ARYL HYDROXY OR KETO THIEPINES. | PHARMACIA CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003040127-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. SEARLE LLC (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1155007-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. Searle LLC (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047568-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. SEARLE LLC (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195218-A1 | Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | KDM4E 1757/4885LMNA 4583/4885CCR1 3376/4885 |
| US-20040067872-A1 | Novel mono- and di-fluorinated benzothiepine compouds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | KDM4E 4299/4885LMNA 4076/4885CCR1 4096/4885 |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | KDM4E 4243/4885LMNA 4622/4885CCR1 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.